Ying Luo was named Chief Executive Officer of Gyre Therapeutics, Inc. As of November 6, 2026, Gyre Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 4, 2026 to July 16, 2026, naming 4 appointments (Form 8-K, May 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Gyre Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Gyre Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-04 to 2026-07-16. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Gyre Therapeutics, Inc. files it.
Also on the record for Gyre Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 7, 2026 | Stake report, Schedule 13D/A, by Songjiang Ma | 6.33% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13D/A, by GNI Group Ltd. | 69.1% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13D/A, by Ying Luo | 8.6% of the class | 5%+ stakes | Source |
| May 4, 2026 | Acquired Cullgen Inc. | — | Acquisition | Source |
Selling to them or working with them? See who runs Gyre Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Gyre Therapeutics, Inc. and the records around it.
Gyre Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Acquisition May 2026
- Who owns it
Watch Gyre Therapeutics, Inc.
Get an email when Gyre Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Gyre Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Gyre Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gyre Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-16 | In | Director | 2026-08-01 | 8-K, 2026-07-16 | |
| 2026-05-04 | In | Chief Executive Officer | 8-K, 2026-05-04 | ||
| 2026-05-04 | In | Chief Financial Officer | 8-K, 2026-05-04 | ||
| 2026-05-04 | In | 8-K, 2026-05-04 |
Who leads Gyre Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Yue Xiong, appointed, effective 2026-08-01 (filed 2026-07-16).
- Chief Financial Officer: Thomas Eastling, appointed (filed 2026-05-04).
- Chief Executive Officer: Ying Luo, appointed (filed 2026-05-04).
New leaders reset buying decisions — get the Full Report on Gyre Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Gyre Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Gyre Therapeutics, Inc.Every change, in the filing's words
Appointed: Yue Xiong, Director, effective 2026-08-01
On July 10, 2026, the board of directors (the "Board") of Gyre Therapeutics, Inc. (the "Company") appointed Yue Xiong, Ph.D. as a Class I director of the Company, Maxwell Kirkby as a Class II director of the Company and Claire Weston, Ph.D. as a Class III director of the Company, in each case effective as of August 1, 2026.
- Mr. Kirkby was also appointed to serve on the Compensation Committee of the Board and Dr. Weston was appointed to serve on the Audit Committee of the Board.
- Mr. Kirkby and Dr. Weston will each receive an initial grant of stock options to purchase 40,000 shares of our common stock, vesting in equal monthly installments over three years, and will be entitled to receive cash compensation in accordance with the Company's non-employee director compensation policy as generally described in the Company's Definitive Proxy Statement filed on April 27, 2026.
- Dr. Xiong previously entered into the Company's standard form of indemnification agreement in connection with his appointment as the Company's Chief Scientific Officer and will receive no additional compensation for his service on the Board.
- Xiong and Weston and any director or executive officer of the Company; and none of Mr. Kirkby or Drs.
Appointed: Ying Luo, Chief Executive Officer
Appointment of Director and Chief Executive Officer and President In accordance with the Merger Agreement, effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.
Appointed: Thomas Eastling, Chief Financial Officer
On May 4, 2026, the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
Appointed: Ying Luo
Nominating and Corporate Governance Committee In connection with the closing of the Merger (the "Closing"), Dr. Luo was appointed Chair of the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee").
- Resignation of Directors In accordance with the Merger Agreement, immediately prior to the Effective Time, Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his position as President of the Company on such date.
- The resignations are not the result of any disagreements with the Company relating to the Company's operations, policies or practices.
- The size of the Board was reduced to seven directors.
- Ping Zhang, the Company's former Interim Chief Executive Officer and Executive Chairman, will continue as Chairman of the Board.
- Effective as of the Closing, the other members of the Nominating Committee are Dan Weng and Gordon Carmichael.
- Compensatory Plan In connection with the Merger, the Cullgen Inc. Stock Incentive Plan (the "Cullgen Stock Plan") as well as all in-the-money stock options that were granted and outstanding under the Cullgen Stock Plan were assumed by the Company and converted into stock options in respect of shares of Company Common Stock.
Tools for this story
Each opens in a new tab, filled in for Gyre Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.